Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition:   Asthma
Interventions:   Drug: 50 mcg salmeterol HFA MDI;   Drug: placebo;   Drug: 5 mcg tiotropium Respimat®;   Drug: 2.5 mcg tiotropium Respimat®
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Leave a Reply

Your email address will not be published. Required fields are marked *